|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 300.20 SEK | -0.46% |
|
-5.78% | -3.41% |
| 14/07 | Bioarctic: LEADER study shows more than 82 percent of Leqembi patients remained stable or improved | FW |
| 14/07 | Leqembi can now be administered at home from the start of treatment in the US | FW |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Biotechnology | 2.57Cr | 23Cr | 62Cr | 26Cr | 199.91Cr | |||||
Total Assets | 90Cr | 86Cr | 118.61Cr | 111.17Cr | 257.52Cr | |||||
Interest Expense | -8L | -6L | -3L | - | -20.26L | |||||
Income Tax Expense | -2.07Cr | 11T | 4.72Cr | -1.24Cr | 23Cr | |||||
CAPEX | -43.86L | -1.27Cr | -74.43L | -2.66Cr | -1.02Cr | |||||
EBT | -14Cr | -1.12Cr | 28Cr | -19Cr | 125.56Cr | |||||
Gross Profit | - | - | - | 23Cr | 193.99Cr | |||||
D&A | 1.35Cr | 1.42Cr | 74.39L | 1.07Cr | 1.52Cr | |||||
Operating Income | -14Cr | -1.74Cr | 25Cr | -23Cr | 125.88Cr | |||||
Net Income | -12Cr | -1.12Cr | 23Cr | -18Cr | 102.23Cr |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
North America | - | - | - | 14Cr | 132.49Cr | |||||
Asia | 1.47Cr | 17Cr | 62Cr | 10Cr | 59Cr | |||||
Europe | 84.66L | 5.85Cr | - | 1.17Cr | 8.02Cr | |||||
Others | - | - | - | 47T | 3L |
- Stock Market
- Stocks
- BIOA B Stock
- Financials BioArctic AB
- Business Segments
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition